These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9444403)

  • 21. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
    Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--I. Gram-positive bacteria].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Apr; 55(2):139-53. PubMed ID: 12071093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
    Suzuki Y; Nishinari C; Endo H; Tamura C; Jinbo K
    Jpn J Antibiot; 2001 Sep; 54(9):473-90. PubMed ID: 11729712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effects of an injectable new quinolone, pazufloxacin, against polymicrobial infections in the uterine endometritis model.
    Mikamo H; Kawazoe K; Sato Y; Tamaya T
    Chemotherapy; 1998; 44(2):99-102. PubMed ID: 9551239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
    Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
    Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activity and beta-lactamase stability of a new carbapenem, BO-2727.
    Inoue K; Hamana Y; Mitsuhashi S
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2331-6. PubMed ID: 8619591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins].
    Nagashima M; Goto S; Yoshida T; Matsunaga T; Shimohira H; Ogawa M
    Jpn J Antibiot; 1996 Apr; 49(4):303-23. PubMed ID: 8786623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antibacterial activities of telithromycin.
    Mikamo H; Yin XH; Ninomiya M; Tamaya T
    Chemotherapy; 2003 May; 49(1-2):62-5. PubMed ID: 12714813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibacterial activity of biapenem against recent clinical isolates].
    Hara T; Araake M; Watabe H
    Jpn J Antibiot; 2003 Apr; 56(2):138-41. PubMed ID: 12825414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].
    Suzuki Y; Nishinari C; Endo H; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Aug; 56(4):309-35. PubMed ID: 14567255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
    Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
    Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
    Ednie L; Shapiro S; Appelbaum PC
    Diagn Microbiol Infect Dis; 2007 May; 58(1):133-6. PubMed ID: 17240107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.